



NEWS RELEASE

Evolus to Participate in the Virtual SVB Securities Global Biopharma Conference

1/31/2023

NEWPORT BEACH, Calif., January 31, 2023 – Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of its management team will be participating in the Virtual SVB Securities Global Biopharma Conference.

Event: Virtual SVB Securities Global Biopharma Conference.
Date: Tuesday, February 14, 2023
Time: 11:20-11:50 am ET

An audio webcast of this event will be available on the investor relations section of Evolus' website at www.evolus.com. A replay of the webcast will be available for 90 days after the date of the presentation.

About Evolus, Inc.

Evolus (Nasdaq: EOLS) is a performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global, multi-product aesthetics company based on our flagship product, Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Visit us at www.evolus.com and follow us on [LinkedIn](#), [Twitter](#), [Instagram](#) or [Facebook](#).

Jeuveau® is a registered trademark of Evolus, Inc.

Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.

Investor/Media Contact:

David K. Erickson, Evolus, Inc.

Vice President, Investor Relations

Tel: 949-966-1798

Email: **david.erickson@evolus.com**

Media Contact:

Email: **media@evolus.com**

Source: Evolus